Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Background: Preterm birth (PTB) remains the leading cause of neonatal mortality and long term disability throughout the world. Recently treatments early in pregnancy such as progesterone, cervical support and maternal support have been demonstrated to delay delivery amongst at risk women. Nonetheless, the majority of women who are at risk are not identified using current screening modalities.
Hypothesis: A cohort of pregnancies who are screened using the PreTRM® test around 20 weeks gestation in which a bundle of interventions is given for elevated PreTRM® risk will show either decreased neonatal morbidity/and mortality (measured as a composite score, "NMI"), or decreased length of neonatal stay in the hospital (NNOLOS). Secondarily, they will show an increase in gestational age at birth (GAB) and a reduction in length of neonatal NICU stay (NICULOS), compared to an unscreened historical control group.
Study Design Type: Prospective cohort study of screened women compared to a historical control of 10000 women.
Population: Women who are 18 years or older, with a singleton pregnancy between 195/7 weeks and 206/7 weeks gestational age (GA) confirmed by ultrasound prior to enrollment, and no history of prior preterm birth (delivery between 160/7 weeks and 366/7 weeks) will be invited to participate. A comparable population will be identified using a historical control group in a contemporaneously maintained database.
Intervention: Qualifying women will be screened using the PreTRM® test (Sera Prognostics, Inc.) at a large tertiary care center. Predicated upon the degree of risk, women will be treated according to a prespecified algorithm. The outcomes of these women will be compared to a historical control group at the same tertiary care center.
Outcomes:
Primary outcome: Co-Primary outcomes: To determine whether a cohort of women who are screened with the PreTRM® test and then managed according to a prespecified protocol will have statistically significant reductions in either (a) composite neonatal morbidity and mortality (NMI score), or (b) length of neonatal hospital stay (NNOLOS), compared to a historical control group. The NMI is defined below
DEFINITIONS OF COMPOSITE PERINATAL MORTALITY/NEONATAL MORBIDITY OUTCOME SCORES:
1) 0 to 4 scale without NICU: This score was derived as an ordinal scale based upon severity. The score was defined by the following: 0 = no events;
2) 0 to 4 scale with NICU: This score was defined as the following: 0 = no events,
3) 0 to 6 scale without NICU: This score was defined as the following: 0 = no events;
4) Any morbidity or mortality event: (yes/no)
Secondary outcomes: To determine whether women who are screened with the PreTRM® test and then managed according to a pre-specified treatment algorithm will have a statistically significant reduction in proportion of any type of preterm births (spontaneous and indicated), the total length of hospital stay for spontaneous preterm births, and total length of hospital stay for any preterm birth.
Observations:
General Outcomes:
Total cost of hospital care for both the mother and fetus beginning at initiation of care through primary delivery and 28 days of life.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Screened arm | Other | This will be an arm of women who are prospectively screened and receive a risk score for preterm birth. They will be recommended treatment strategies and their outcomes compared to an historical control. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Screened Arm | Other | Woman who are identified as high risk will be advised of potential interventions which will include support through care link(nurse education), cervical surveillance, consider vaginal progesterone, low dose aspirin if not already taking. |
| Measure | Description | Time Frame |
|---|---|---|
| Neonatal Mortality Index | Outcomes: Co primary outcomes will consist of the Neonatal Morbidity Index as defined by Hassan and Neonatal NICU length of stay | Birth through 6 months |
| Neonatal NICU length of stay | Duration of hospitalization in the NICU | Birth to 6 months |
| Measure | Description | Time Frame |
|---|---|---|
| Preterm birth | Preterm birth before 37 weeks | Through pregnancy completion, typically 42 weeks |
| Total length of hospital stay for any preterm birth | Total length of hospital stay for any preterm birth |
| Measure | Description | Time Frame |
|---|---|---|
| Neonatal death and stillbirth | Neonatal death and stillbirth | Through 42 days post delivery |
| Birthweight and if birthweight was <1500g | birthweight below 1500 and 2500gm |
Inclusion Criteria:
Exclusion Criteria:
requires pregnancy
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Matthew K Hoffman, MD | ChristianaCare | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Christiana Hospital | Newark | Delaware | 19718 | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 14626726 | Background | Anderson RN, Smith BL. Deaths: leading causes for 2001. Natl Vital Stat Rep. 2003 Nov 7;52(9):1-85. | |
| 21446209 | Background | Berghella V, Rafael TJ, Szychowski JM, Rust OA, Owen J. Cerclage for short cervix on ultrasonography in women with singleton gestations and previous preterm birth: a meta-analysis. Obstet Gynecol. 2011 Mar;117(3):663-671. doi: 10.1097/AOG.0b013e31820ca847. |
Not provided
Not provided
IPD will potentially be shared with a like study being conducted at the University of Utah
Not provided
Not provided
Not provided
Not provided
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| SAP | No | Yes | No | Statistical Analysis Plan | Jul 11, 2022 | Jul 11, 2022 | SAP_002.pdf |
Not provided
| ID | Term |
|---|---|
| D047928 | Premature Birth |
| ID | Term |
|---|---|
| D007752 | Obstetric Labor, Premature |
| D007744 | Obstetric Labor Complications |
| D011248 | Pregnancy Complications |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
Not provided
Not provided
Women who are found to have an elevated risk of preterm birth will receive counseling regarding potential interventions and compared to historical controls
Not provided
Not provided
Not provided
Not provided
| From birth to 60 days post delivery |
| At time of delivery |
| Birthweight and if birthweight was <2500gm | birthweight below 2500gm | At time of delivery |
| Whether or not received surfactant and amount of surfactant | Whether baby got surfactant | Through hospitalization or 60 days post delivery |
| Occurrence of pneumonia | Occurrence of pneumonia | Through hospitalization or 60 days post delivery |
| Number of days of mechanical ventilation | days on mechanical ventilation | Through hospitalization or 60 days post delivery |
| Occurrence of 5 minute Apgar<7 | low apgar as defined | At time of birth |
| Occurrence of asphyxia, diagnosed either via intrapartum cord gas or via clinical findings | Occurrence of asphyxia, | At tiem of birth |
| Occurrence of preterm delivery at <37, <35 and <32 weeks | Occurrence of preterm delivery at <37, <35 and <32 weeks | At time of birth |
| Occurrence of preeclampsia | preeclampsia as defined by ACOG | Through 60 days post delivery |
| Progesterone levels determined by LC-MS | progesterone levels | at 32 weeks |
| 7906809 | Background | CLASP: a randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) Collaborative Group. Lancet. 1994 Mar 12;343(8898):619-29. |
| 28291893 | Background | Esplin MS, Elovitz MA, Iams JD, Parker CB, Wapner RJ, Grobman WA, Simhan HN, Wing DA, Haas DM, Silver RM, Hoffman MK, Peaceman AM, Caritis SN, Parry S, Wadhwa P, Foroud T, Mercer BM, Hunter SM, Saade GR, Reddy UM; nuMoM2b Network. Predictive Accuracy of Serial Transvaginal Cervical Lengths and Quantitative Vaginal Fetal Fibronectin Levels for Spontaneous Preterm Birth Among Nulliparous Women. JAMA. 2017 Mar 14;317(10):1047-1056. doi: 10.1001/jama.2017.1373. |
| 19301566 | Background | Rittenberg C, Newman RB, Istwan NB, Rhea DJ, Stanziano GJ. Preterm birth prevention by 17 alpha-hydroxyprogesterone caproate vs. daily nursing surveillance. J Reprod Med. 2009 Feb;54(2):47-52. |
| 26874297 | Background | Saade GR, Boggess KA, Sullivan SA, Markenson GR, Iams JD, Coonrod DV, Pereira LM, Esplin MS, Cousins LM, Lam GK, Hoffman MK, Severinsen RD, Pugmire T, Flick JS, Fox AC, Lueth AJ, Rust SR, Mazzola E, Hsu C, Dufford MT, Bradford CL, Ichetovkin IE, Fleischer TC, Polpitiya AD, Critchfield GC, Kearney PE, Boniface JJ, Hickok DE. Development and validation of a spontaneous preterm delivery predictor in asymptomatic women. Am J Obstet Gynecol. 2016 May;214(5):633.e1-633.e24. doi: 10.1016/j.ajog.2016.02.001. Epub 2016 Feb 11. |
| 28067007 | Background | Romero R, Conde-Agudelo A, El-Refaie W, Rode L, Brizot ML, Cetingoz E, Serra V, Da Fonseca E, Abdelhafez MS, Tabor A, Perales A, Hassan SS, Nicolaides KH. Vaginal progesterone decreases preterm birth and neonatal morbidity and mortality in women with a twin gestation and a short cervix: an updated meta-analysis of individual patient data. Ultrasound Obstet Gynecol. 2017 Mar;49(3):303-314. doi: 10.1002/uog.17397. |
| D000091642 | Urogenital Diseases |